The ADDUCE Consortium

Members

INSERM

Institut National pour la Santé et la Recherche Biomédical

Maison de Solenn

97 boulevard du Port royal

75679 Paris cedex 14

France

Homepage

Project leader

Prof. Bruno Falissard

Phone: +33 6818 270 76

Fax: +33 6818 270 76

Description of the organization

The Institut National pour la Santé et la Recherche Biomédicale (INSERM) is the French organisation dedicated to health research in France.

Previous experience

Prof. Falissard was the Principal Investigator of the MHP study (Mental Health in Prison, 2003‐2007). He has been and is co‐investigator/methodological advisor on more than 30 research projects that have led to publications in international peer reviewed journals.

Profile of staff members

Prof. Falissard is Professor in Public Health/Biostatistics at the South Paris University and has been the Head of the Public Health Department of Paul Brousse Hospital since 1999. Prof. Falissard was certified in Psychiatry in 1996, received his PhD in Biostatistics in 1990 and his degree from the “Ecole Polytechnique” in Paris in 1985. He has been the Head of INSERM U669 (PSIGIAM, Paris Sud Innovation Group in Adolescents Mental Health), a laboratory comprising of 110 members, since 2005. Prof. Falissard sits on the scientific boards of many foundations, as well as the Board of the International Journal of Methods in Psychiatric Research and is Statistical Advisor to the European Psychiatry Journal. He is past president of the scientific board of “Faculté de Médecine Paris‐Sud” and has co‐authored more than 130 papers indexed in the PubMed database.

Main tasks in the project

Prof. Falissard will assist the clinical WPs (5‐8), WP3 and WP4 in addressing the questions of design, data management and statistical analysis plans.

News

The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!

In this newsletter, you can find some information on the final recruitment status of the 2 main studies:

- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use

Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!